Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes.
The degradation of ANG II by angiotensin-converting enzyme 2 (ACE2), leading to the formation of ANG(1-7), is an important step in the regulation of the renin-angiotensin-aldosterone system (RAAS), and one that is significantly altered in the diabetic kidney. This study examined the role of ACE2 in the hyperfiltration associated with diabetes. Streptozotocin diabetes was induced in male C57BL6 mice and ACE2 knockout (KO) mice. C57BL6 mice were further randomized to receive the selective ACE2 inhibitor MLN-4760. After 2 wk of study, animals were subjected to micropuncture experiments. The renal reserve was further assessed in C57BL6 mice and ACE2 KO mice after exposure to a high-protein diet. The induction of diabetes in wild-type mice was associated with increased renal ACE2 activity, hyperfiltration, and renal hypertrophy. On micropuncture, diabetes was associated with increased tubular free flow and stop-flow pressure, enhanced tubuloglomerular feedback reactivity, and an increased maximal response indicative of increased glomerular hydrostatic capillary pressure. Each of these increases were prevented in diabetic ACE2 KO mice and diabetic mice treated with a selective ACE2 inhibitor for 2 wk. However, unlike chronically treated animals, ACE2 inhibition with MLN-4760 had no acute effect on stop-flow pressure or tubuloglomerular feedback reactivity. ACE2 KO mice also failed to increase their creatinine clearance in response to a high-protein diet. The results of our study suggest that ACE2 plays a key role in the recruitment of the renal reserve and hyperfiltration associated with diabetes.
Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Central, Melbourne 8008, Victoria, Australia. Merlin.Thomas@bakeridi.edu.au.
Chris
C
Tikellis
Russel
R
Brown
Geoffrey A
GA
Head
Mark E
ME
Cooper
Merlin C
MC
Thomas
D000085962:Angiotensin-Converting Enzyme 2; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D002196:Capillaries / Q000503:physiopathology; D003404:Creatinine / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D004044:Dietary Proteins / Q000378:metabolism; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006874:Hydrostatic Pressure; D006984:Hypertrophy; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D007703:Peptidyl-Dipeptidase A / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D012079:Renal Circulation; D012084:Renin-Angiotensin System
D000806:Angiotensin-Converting Enzyme Inhibitors; D004044:Dietary Proteins; D003404:Creatinine; D007703:Peptidyl-Dipeptidase A; C000705328:Ace2 protein, mouse; D000085962:Angiotensin-Converting Enzyme 2
angiotensin; angiotensin-converting enzyme 2; diabetes; diabetic nephropathy; hyperfiltration; micropuncture